Proteinase-Activated Receptor-1 and Immunomodulatory Effects of a PAR1-Activating Peptide in a Mouse Model of Prostatitis

Figure 7

Instillation of the PAR1 activating peptide TFLLR-NH₂ significantly increases IL-10 concentration in the inflamed prostates of wild-type but not PAR1^−/− mice and does not change IL-10 levels in serum. Prostates were treated with sterile saline in wild-type mice (saline), ethanol + dinitrobenzene sulfonic acid in wild-type mice (EtOH + DNBS), ethanol + dinitrobenzene sulfonic acid + PAR1 reverse peptide RLLFT-NH₂ in wild-type mice (EtOH + DNBS + PAR1 RL), ethanol + dinitrobenzene sulfonic acid + PAR1 activating peptide TFLLR-NH₂ in PAR1 knockout mice (EtOH + DNBS + PAR1 TF PAR1^−/−), or ethanol + dinitrobenzene sulfonic acid + PAR1 activating peptide TFLLR-NH₂ in wild-type mice (EtOH + DNBS + PAR1 TF) for 2 days. The inflammatory response was measured by monitoring (a) prostatic interleukin-10 (IL-10), and (b) serum IL-10. Data are mean ± SEM of 𝑛=4–7 per group. *𝑃<0.05, ***𝑃<0.001 for treatment groups versus saline; ^##𝑃<0.01 for EtOH + DNBS + PAR1 TF versus EtOH + DNBS; ^∧𝑃<0.05 for EtOH + DNBS + PAR1 TF versus EtOH + DNBS + PAR1 RL; ^$𝑃<0.05 for EtOH + DNBS + PAR1 TF versus EtOH + DNBS + PAR1 TF PAR1^−/−.

(a)

(b)